Testing RBS2418 with supportive care in advanced colorectal cancer
Tests RBS2418 against a placebo in adults with advanced colorectal cancer.
Plain-language title generated from the registry record
Registry title: Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
Key facts
- Where
- Kingwood, Las Vegas, Nashville, and Newark, United StatesSee the 4 sites
- Phase
- Phase 2
Where in United States
- Community Clinical TrialsKingwood, United StatesTaking people
- Comprehensive Cancer Centers of NevadaLas Vegas, United StatesTaking people
- SCRI Oncology LLCNashville, United StatesTaking people
- Christiana CareNewark, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Riboscience, LLC.
- Trial code
- NCT06824064
- Record updated
- 5 November 2026
- Original description
RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and leading to the activation of antigen-presenting cells followed by T cell activation. The hypothesis is that RBS2418 versus placebo will be generally safe, well-tolerated, immunogenic, and will lead to anti-tumor responses in adult subjects for the treatment of advanced, metastatic, and progressive colorectal cancer (CRC).Read full original descriptionShow less
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study of RBS2418 Plus Best Supportive Care (BSC) in Subjects With Advanced, Metastatic, and Progressive Colorectal Cancer
RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and leading to the activation of antigen-presenting cells followed by T cell activation. The hypothesis is that RBS2418 versus placebo will be generally safe, well-tolerated, immunogenic, and will lead to anti-tumor responses in adult subjects for the treatment of advanced, metastatic, and progressive colorectal cancer (CRC).
Inclusion: At least 18 years of age on the day of signing informed consent; Male and female subjects with advanced, metastatic, progressive CRC who have received, been ineligible for, intolerant to, or declined all approved standard of care (SOC) therapies for metastatic CRC, as per local SOC treatment regimens. Additionally, subjects must have documented PD based on two scans performed within 2 to 4 months of study initiation; Have histologically or cytologically confirmed CRC diagnosis based on pathology report; Willing to submit a pre-treatment tissue sample (archival, or fresh tissue if archival is not available).
Exclusion: Any approved anti-cancer therapy including chemotherapy, targeted small molecule therapy, systemic immunotherapy, or radiation therapy within 2 weeks prior to the first dose of study treatment; or if subject has not recovered (i.e., ≤ to Grade 1 or returned to baseline level) from AEs due to a previously administered agent; the following exceptions are allowed:; Palliative radiotherapy for bone metastases or soft tissue lesions should be completed >7 days prior to the first dose of study treatment; Hormone-replacement therapy or oral contraceptives; Subjects with Grade 2 neuropathy or Grade 2 alopecia; Subjects with evidence of rapid progression on prior therapy resulting in rapid clinical deterioration; Malignancies other than indications open for enrollment within 3 years prior to Day 1, except for those with negligible risk of metastasis or death treated with expected curative outcome, undergoing active surveillance, or treatment-naïve for indolent tumors.